9-105617967-C-T
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_001079802.2(FKTN):c.919C>T(p.Arg307*) variant causes a stop gained change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000629 in 1,431,632 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_001079802.2 stop_gained
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
FKTN | NM_001079802.2 | c.919C>T | p.Arg307* | stop_gained | 9/11 | ENST00000357998.10 | NP_001073270.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
FKTN | ENST00000357998.10 | c.919C>T | p.Arg307* | stop_gained | 9/11 | 5 | NM_001079802.2 | ENSP00000350687.6 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD3 exomes AF: 0.0000201 AC: 5AN: 248994Hom.: 0 AF XY: 0.0000148 AC XY: 2AN XY: 134826
GnomAD4 exome AF: 0.00000629 AC: 9AN: 1431632Hom.: 0 Cov.: 25 AF XY: 0.00000980 AC XY: 7AN XY: 714230
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 4 Pathogenic:5
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Mar 18, 2019 | Variant summary: FKTN c.919C>T (p.Arg307X) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as likely pathogenic/pathogenic by our laboratory (eg. c.1106delT (p.Phe369fsX37) and c.1167dupA (p.Phe390fsX14)). The variant allele was found at a frequency of 2e-05 in 244338 control chromosomes (gnomAD). c.919C>T has been reported in the literature in individuals affected with Walker-Warburg Syndrome, Fukuyama-type congenital muscular dystrophy, and unexplained limb-girdle muscle weakness (Godfrey_2007, Yoshioka_2008, Johnson_2018). These data indicate that the variant is likely to be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. A ClinVar submission from a clinical diagnostic laboratory (evaluation after 2014) cites the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Victorian Clinical Genetics Services, Murdoch Childrens Research Institute | Dec 21, 2023 | Based on the classification scheme VCGS_Germline_v1.3.4, this variant is classified as Pathogenic. Following criteria are met: 0102 - Loss of function is a known mechanism of disease in this gene and is associated with muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 4 (MIM# 253800), muscular dystrophy-dystroglycanopathy (congenital without impaired intellectual development), type B, 4 (MIM# 613152), and muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 4 (MIM# 611588). The association to cardiomyopathy, dilated, 1X (MIM# 611615) is not established (PanelApp). (I) 0106 - This gene is associated with autosomal recessive disease. (I) 0201 - Variant is predicted to cause nonsense-mediated decay (NMD) and loss of protein (premature termination codon is located at least 54 nucleotides upstream of the final exon-exon junction). (SP) 0251 - This variant is heterozygous. (I) 0304 - Variant is present in gnomAD (v2) <0.01 for a recessive condition (5 heterozygotes, 0 homozygotes). (SP) 0701 - Other NMD-predicted variants comparable to the one identified in this case have very strong previous evidence for pathogenicity (DECIPHER). (SP) 0801 - This variant has strong previous evidence of pathogenicity in unrelated individuals. This variant has been reported many times as pathogenic, and observed in individuals with Walker-Warburg Syndrome, Fukuyama-type congenital muscular dystrophy, and limb-girdle muscular dystrophy (ClinVar). (SP) 1205 - This variant has been shown to be maternally inherited (by trio analysis). (I) Legend: (SP) - Supporting pathogenic, (I) - Information, (SB) - Supporting benign - |
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | - | - - |
Pathogenic, no assertion criteria provided | clinical testing | Counsyl | Aug 19, 2016 | - - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Oct 01, 2007 | - - |
not provided Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Mar 19, 2023 | Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss of function is a known mechanism of disease; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 25525159, 20961758, 34426522, 35843586, 30060766, 32528171, 33051673, 17878207, 17597323) - |
Pathogenic, no assertion criteria provided | clinical testing | Genome Diagnostics Laboratory, University Medical Center Utrecht | - | - - |
Pathogenic, no assertion criteria provided | clinical testing | Genome Diagnostics Laboratory, Amsterdam University Medical Center | - | - - |
Walker-Warburg congenital muscular dystrophy Pathogenic:2
Pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Jun 20, 2017 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Nov 25, 2023 | This sequence change creates a premature translational stop signal (p.Arg307*) in the FKTN gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in FKTN are known to be pathogenic (PMID: 17044012, 17878207, 18752264). This variant is present in population databases (rs267606814, gnomAD 0.01%). This premature translational stop signal has been observed in individuals with Fukuyama-type congenital muscular dystrophy and/or Walker-Warburg syndrome (PMID: 17597323, 17878207). ClinVar contains an entry for this variant (Variation ID: 3216). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. - |
Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 4;C1969024:Dilated cardiomyopathy 1X;C1969040:Autosomal recessive limb-girdle muscular dystrophy type 2M;C2751052:Muscular dystrophy-dystroglycanopathy (congenital without intellectual disability), type B4 Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Apr 12, 2024 | - - |
Muscular dystrophy-dystroglycanopathy (congenital without intellectual disability), type B4 Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Juno Genomics, Hangzhou Juno Genomics, Inc | - | PM2_Supporting+PVS1+PM3_Strong - |
Dilated cardiomyopathy 1X Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Mar 30, 2024 | - - |
Cardiovascular phenotype Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Sep 09, 2020 | The p.R307* pathogenic mutation (also known as c.919C>T), located in coding exon 7 of the FKTN gene, results from a C to T substitution at nucleotide position 919. This changes the amino acid from an arginine to a stop codon within coding exon 7. This mutation was first reported in a homozygous Turkish case with severe neonatal onset Walker-Warburg syndrome (Godfrey C et al. Brain, 2007 Oct;130:2725-35). This mutation has also been detected in a compound heterozygous Fukuyama-type congenital muscular dystrophy case and a compound heterozygous limb girdle muscular dystrophy case with confirmed α-DG deficiency (Yoshioka M et al. Brain Dev., 2008 Jan;30:59-67; Johnson K et al. Skelet Muscle, 2018 07;8:23). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at